Trabectedina
1. Demetri GD, et al. Eur J Cancer. 2015;vol 51(Supl 3) pages 700 Abs. Nº3436.
2. Le Cesne A, et al. Eur J Cancer. 2015;51(6):742-50;
3. Samuels BL, et al. Ann Oncol. 2013. 24(6):1703-9; 3.
4. López Pousa A et al. Clin Transl Oncol. 2016; 18: 12134-20
Trabectedina tiene indicación en el tratamiento de sarcomas de
partes blandas avanzados tras el fracaso de Doxo / Ifo, o bien en
aquellos pacientes que no sean candidatos a estos fármacos.
“Trabectedin is a second-line option [II, B] and is
approved for advanced previously treated STS in
the EU. It has proved effective in
leiomyosarcoma and liposarcoma
[27]. In myxoid
liposarcoma, a high antitumour activity was
described. A peculiar pattern of tumour response
has been reported, with an early phase of tissue
changes preceding tumour shrinkage [28].
Clinical
benefit with trabectedin was also obtained in
other histological types
Guías
